ATE543492T1 - Behandlung von lungenkrebs - Google Patents

Behandlung von lungenkrebs

Info

Publication number
ATE543492T1
ATE543492T1 AT07849582T AT07849582T ATE543492T1 AT E543492 T1 ATE543492 T1 AT E543492T1 AT 07849582 T AT07849582 T AT 07849582T AT 07849582 T AT07849582 T AT 07849582T AT E543492 T1 ATE543492 T1 AT E543492T1
Authority
AT
Austria
Prior art keywords
lung cancer
treatment
fts
disclosed
analogs
Prior art date
Application number
AT07849582T
Other languages
English (en)
Inventor
Yoel Kloog
Adi Zundelevich
Roni Haklai
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE543492T1 publication Critical patent/ATE543492T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07849582T 2006-12-19 2007-12-17 Behandlung von lungenkrebs ATE543492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87591506P 2006-12-19 2006-12-19
PCT/IL2007/001556 WO2008075342A1 (en) 2006-12-19 2007-12-17 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
ATE543492T1 true ATE543492T1 (de) 2012-02-15

Family

ID=39203260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07849582T ATE543492T1 (de) 2006-12-19 2007-12-17 Behandlung von lungenkrebs

Country Status (6)

Country Link
US (3) US8232253B2 (de)
EP (1) EP2094260B1 (de)
AT (1) ATE543492T1 (de)
CA (1) CA2672839C (de)
MX (1) MX2009006574A (de)
WO (1) WO2008075342A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
EP2094260B1 (de) * 2006-12-19 2012-02-01 Ramot at Tel-Aviv University Ltd. Behandlung von lungenkrebs
WO2011056542A1 (en) * 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
WO2012129281A2 (en) * 2011-03-22 2012-09-27 The General Hospital Corporation Detection of targets using magnetic resonance
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
ES2642843T3 (es) 2011-10-07 2017-11-20 Pisces Therapeutics Llc Tratamiento de enfermedad maligna y no maligna con antagonistas de Ras
US9474730B2 (en) * 2012-04-30 2016-10-25 Board Of Regents Of The University Of Texas System Methods and compositions for use with K-ras mediated disorders
CN104292139B (zh) * 2014-08-25 2016-04-13 南通大学 法尼基硫醚取代的查尔酮衍生物及制备方法和用途
CN104292140B (zh) * 2014-08-25 2016-06-29 南通大学 含有查尔酮骨架的法尼基硫代水杨酸类似物及制备方法和用途
BR112017019918B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para produzir uma preparação sólida farmacêutica para estabilizar uma preparação sólida farmacêutica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
US20040072258A1 (en) * 2000-10-04 2004-04-15 Yoel Kloog Isoprenoid-dependent ras anchorage (idra) proteins
EP2301528B1 (de) 2004-08-18 2013-04-03 Kadmon Corporation, LLC Verwendung von FTS zur Behandlung von malignen Erkrankungen
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
EP2094260B1 (de) * 2006-12-19 2012-02-01 Ramot at Tel-Aviv University Ltd. Behandlung von lungenkrebs

Also Published As

Publication number Publication date
WO2008075342A1 (en) 2008-06-26
US20100136138A1 (en) 2010-06-03
US20140088123A1 (en) 2014-03-27
US20120294957A1 (en) 2012-11-22
CA2672839A1 (en) 2008-06-26
EP2094260B1 (de) 2012-02-01
EP2094260A1 (de) 2009-09-02
CA2672839C (en) 2012-07-03
US8232253B2 (en) 2012-07-31
MX2009006574A (es) 2009-07-02

Similar Documents

Publication Publication Date Title
ATE543492T1 (de) Behandlung von lungenkrebs
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201391286A1 (ru) Лечение солидных опухолей
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
TNSN07419A1 (en) Methods for treating drug resistant cancer
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
MX2009005798A (es) Recuperacion de apoplejia.
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
EA201490199A1 (ru) Терапевтические способы
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии